ArticleExperimental and therapeutic medicine2019
MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Molecular insight into the therapeutic potential of miR-34a in retinoblastoma.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Insights into retinoblastoma pathogenesis: unraveling RB1, N-MYC and miRNA profiles.BMJ open ophthalmology · 2025Article
- PTPN12 down-regulated by miR-146b-3p gene affects the malignant progression of laryngeal squamous cell carcinoma.Open medicine (Warsaw, Poland) · 2023Article
- Tumor Suppressor miRNA-503 Inhibits Cell Invasion in Head and Neck Cancer through the Wnt Signaling Pathway via the WNT3A/MMP Molecular Axis.International journal of molecular sciences · 2022Article
- Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.Frontiers in oncology · 2022Review
- Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma.Human cell · 2022Article
- The Causes and Consequences of miR-503 Dysregulation and Its Impact on Cardiovascular Disease and Cancer.Frontiers in pharmacology · 2021Review
- Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression.Open medicine (Warsaw, Poland) · 2021Article
- MiR-503-5p functions as an oncogene in oral squamous cell carcinoma by targeting Smad7.Histology and histopathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous studies have demonstrated that microRNAs (miRNAs or miRs) are abnormally expressed in retinoblastoma (RB). miRNAs may serve a role in oncogene or tumor-suppressor activity in RB genesis and development by modulating various biological processes. miRNAs therefore, may be effective therapeutic targets for miRNA-based therapy in patients with RB. Recently it has been revealed that miR-503 may serve a role in various types of human cancer. However, the expression and functional roles of miR-503 are rarely reported in RB. In the current study, the expression of miR-503 was significantly upregulated in RB tissues and cell lines. In addition, Cell Counting Kit-8 and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.